From: Treatment patterns and outcomes of older patients with mantle cell lymphoma in an Asian population
Characteristic | Overall survival | Progression-free survival | ||||
---|---|---|---|---|---|---|
HR | 95% CI | p-value | HR | 95% CI | p-value | |
Age ≥ 60 years | 4.30 | 1.92 to 9.63 | 0.0004 | 2.61 | 1.40 to 4.87 | 0.0025 |
Sex (male) | 1.00 | 0.44 to 2.29 | 0.9994 | 0.94 | 0.50 to 1.77 | 0.8554 |
Ethnicity (Chinese) | 0.73 | 0.29 to 1.87 | 0.5160 | 0.86 | 0.42 to 1.75 | 0.6750 |
Smoking history present | 1.01 | 0.30 to 3.38 | 0.9910 | 0.73 | 0.30 to 1.80 | 0.4964 |
B-symptoms present | 1.93 | 0.87 to 4.29 | 0.1061 | 1.26 | 0.68 to 2.34 | 0.4711 |
ECOG 1–4 | 2.53 | 1.12 to 5.71 | 0.0261 | 1.84 | 0.97 to 3.48 | 0.0608 |
Bulky disease > 10 cm | 0.56 | 0.14 to 2.34 | 0.4300 | 0.71 | 0.26 to 1.96 | 0.5136 |
sMIPI intermediate-high | 1.50 | 0.68 to 3.32 | 0.3184 | 1.43 | 0.79 to 2.60 | 0.2423 |
Ann Arbor stage 3–4 | 0.60 | 0.21 to 1.72 | 0.3398 | 1.22 | 0.55 to 2.72 | 0.6314 |
Lymph node involvement ≥ 4 | 0.47 | 0.21 to 1.03 | 0.0598 | 0.99 | 0.55 to 1.78 | 0.9649 |
Extra-nodal involvement | 0.52 | 0.17 to 1.56 | 0.2454 | 0.73 | 0.31 to 1.70 | 0.4621 |
Bone marrow involvement | 0.46 | 0.20 to 1.03 | 0.0586 | 0.59 | 0.32 to 1.11 | 0.1029 |
Spleen involvement | 0.50 | 0.22 to 1.16 | 0.1081 | 0.91 | 0.48 to 1.73 | 0.7723 |
Serum LDH elevated | 1.02 | 0.46 to 2.27 | 0.9529 | 1.59 | 0.88 to 2.87 | 0.1240 |
Hb ≤ 12.4 g/dL | 3.05 | 1.42 to 6.57 | 0.0044 | 2.02 | 1.12 to 3.64 | 0.0190 |
WBC > 10 * 109 cells/L | 1.54 | 0.64 to 3.68 | 0.3311 | 1.24 | 0.64 to 2.40 | 0.5147 |
Albumin < 35 g/L | 1.71 | 0.70 to 4.17 | 0.2412 | 3.11 | 1.48 to 6.51 | 0.0026 |